Understanding the Divergent Data on Postmenopausal Hormone Therapy
- 13 February 2003
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 348 (7), 645-650
- https://doi.org/10.1056/nejmsb022365
Abstract
In contrast to observational studies, randomized clinical trials of hormone-replacement therapy have not shown a cardioprotective effect. The authors propose several methodologic and biologic explanations for these discrepant results.Keywords
This publication has 36 references indexed in Scilit:
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial InfarctionCirculation, 2002
- Effects of Estrogen Replacement on the Progression of Coronary-Artery AtherosclerosisNew England Journal of Medicine, 2000
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancerThe Lancet, 1997
- Prospective study of exogenous hormones and risk of pulmonary embolism in womenThe Lancet, 1996
- Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular DiseaseNew England Journal of Medicine, 1996
- Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaquesAmerican Journal of Obstetrics and Gynecology, 1996
- Coronary heart disease and estrogen replacement therapy can compliance bias explain the results of observational studies?Annals of Epidemiology, 1994
- Decreased mortality in users of estrogen replacement therapyArchives of Internal Medicine, 1991